How Smart Investors Look at AstraZeneca PLC (AZN).

By Ken Smith • Wednesday, April 19 09:42 • Permanent Link

Large-cap Health Care company AstraZeneca PLC has moved -0.6% so far today on a volume of 517,458, compared to its average of 4,949,993. In contrast, the S&P 500 index moved -0.0%.

AstraZeneca PLC trades -3.49% away from its average analyst target price of $77.29 per share. The 7 analysts following the stock have set target prices ranging from $65.0 to $88.0, and on average have given AstraZeneca PLC a rating of buy.

Anyone interested in buying AZN should be aware of the facts below:

AstraZeneca PLC's current price is 1225.2% above its Graham number of $5.63, which implies that at its current valuation it does not offer a margin of safety
AstraZeneca PLC has moved 9.0% over the last year, and the S&P 500 logged a change of -6.8%
Based on its trailing earnings per share of 1.05, AstraZeneca PLC has a trailing 12 month Price to Earnings (P/E) ratio of 71.0 while the S&P 500 average is 15.97
AZN has a forward P/E ratio of 17.4 based on its forward 12 month price to earnings (EPS) of $4.28 per share
The company has a price to earnings growth (PEG) ratio of 1.53 — a number near or below 1 signifying that AstraZeneca PLC is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 37.6 compared to its sector average of 4.16
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Based in Cambridge, the company has 83,500 full time employees and a market cap of $233,830,711,296. AstraZeneca PLC currently returns an annual dividend yield of 3.9%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.